18 Sep, 2018 · In News
06 Dec, 2018 · In Press Releases
World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies
28 Nov, 2018
During an additional shareholder meeting on October 9, 2018 it was decided to issue warrants to establish a stock option program for employees in Bioservo Technologies AB (publ).
The program has been fully subscribed and 385 710 warrants have been issued
The CEO, senior executives and other key employees have acquired the number of warrants offered, in accordance with the shareholder meetings decision.
The subscription price amounted to SEK 1.09 per warrant. The share capital has increased by SEK
77 142 corresponding to a dilution of approximately 4.3 percent, based on the existing number of outstanding shares and votes in Bioservo.
Each warrant entitles the owner to acquire a share in Bioservo at the subscription price of SEK 30. The subscription of shares may take place during the following periods:
- from the day after Bioservo has published its quarterly report for the fourth quarter of 2022 until March 15, 2023;
- from the day after Bioservo has published its quarterly report for the first quarter of 2023 until
June 15, 2023;
- from the day after Bioservo has published its quarterly report for the second quarter of 2023 until September 15, 2023; and
- from the day after Bioservo has published its quarterly report for the third quarter of 2023 until December 15, 2023.
The number of shares eligible for the warrants and the subscription price may be recalculated in the event of, for example, extraordinary dividend, bonus issue, aggregation or division of shares, new issue with preferential right for the shareholder or certain forms of reduction of the share capital or similar measures.
For more information, please contact
+46 (0)70 555 69 97
+46 (0) 70 622 54 93
Bioservo Technologies in brief
Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimise the body’s endurance and performance, or for people with reduced muscle strength.
After many years of research and development, Bioservo Technologies is now focused on a commercialisation of the company’s products and patented technologies. The gloves are well-suited to medical rehabilitation, and to preventive use by healthcare professionals. The company has, for example, signed strategic partnership agreements with several multinational companies within the automotive and aerospace industry as well as companies active in construction/ infrastructure.
Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public limited company with its headquarters and operations based in Kista, north of Stockholm.
For more information, please visit www.bioservo.com